Photo Credit: Peakstock
The Following is a summary of “Interaction Between apoe ɛ Status, Chemotherapy and Endocrine Therapy on Cognitive Functioning Among Brease Cancer Survivors: The Canto-Cog Longitudinal Study,” Published in the Februar 2025 Issue of the Breast Cancer Research by Duvon et al.
The Presence of the Apolipoprotein and ε4 (APOE4) Genotype has Been Associated with an Increated Risk of Cancer-Relanted Cognitive Impairment; However, ITS Interaction with Specific Breast Cancer Treatments Remains Uncertain. This longitudinal Study Investigates The Relationship Beteen Apoe4 and Cognitive Function in Women Undergoing Chemotherapy And/or Endocrine Therapy for Breast Cancer, Aiming to Determine Whether Apoe4 Status Influences Decline Over Time.
The Total of 334 Women Diagnosed with Stage I-III Breast Cancer Underwent Cognitive Assessments at Four-Time Points: Baseline (at Diagnosis, Prior to Surgery), and at One, Two, and Four Years Post-Diagnosis. APOE4 status was determined through Blood Sample Genotyping, Categorizing Participants AS EITHER APOE4 CARRIERS (APOE4+) OR NON-CARRIERS (APOE4−). The Cognitive Domains Evaluated Included Episodic Memory, Working Memory, Attention, Processing Speed, and Executive Function. Overall Cognitive Impairment was defined as impairment in at least two cognitive tameins. Logistics and Linear Mixed Models Were Utilized to Assess the Associations Beteen Apoe4 Status and Cognitive Impairment Over Time, as wells as potential interactions bete4 and ct or et.
Among the 334 Participants, 64 (19%) WERE APOE4 Carriers. Treatment Distribution Included 117 (35%) Paths Receue CT Alone, 41 (12%) Receiving et Alone, and 162 (49%) Receiving A Combination of CT and et. The Analysis Revealed on Significant Association Beteen Apoe4 Status and Overall Cognitive Impairment, Nor Any Significant Interactions Between APOE4 and CT or et in Relationship to Global Cognitive Function. However, at the Four-Year Follow-Up, Patients with Apoe4+ Who Received et Exhibited Significantly Lower Attention Performance Compreded to Patients with APOE4− Who Did Not Receive et. Addihthanly, Patients with APOE4+ Who Were Not Treated with et Demoned Lower Episodic Memory Performance Than Their Apoe4− Counterparts Who Were Also Not Treated with et. These Findings Suggest That While Apoe4 Alone Does Not Strongly Predict Overall Cognitive Impairment in Patients with Breast Cancer, Specific Cognitive Domains May Be Affected Depending on et Exposure and APOE4 Status.
In conclusion, Apoe4 genotyping does not appear to be a reliable predictor of treatment-related cognitive impairment in women with crown cancer. These Findings Highlight the Need for Further Research to Identify Alternative Genetic or Biological Markers That May Better Predict Cognitive Decline Associated with Cancer Therapies. Understanding these risk factors could help develoop targeted interventions to mitigate cognitive dysfunction in pacients with brain cancer prescription ct and et.
Source: Breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-01974-2
